DRKS00024523已完成不适用
Prospective, multi-center, single-arm, open-label, observational study forEvaluation of Performance and Safety of the BICOM optima / BICOMoptima Mobil device for bioresonance treatment in patients with allergicrhino-conjunctivitis.
Regumed- Regulative Medizintechnik GmbH0 个研究点目标入组 127 人开始时间: 2021年3月3日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 127
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 4 Years 至 one（—）
- 性别
- All
入选标准
- •Based on clinical practice:
- •(a) symptomatic seasonal or persistent allergic rhino-conjunctivitis without severe asthma
- •b) patient with mild to moderate allergic symptoms
- •c) The therapist expects that treatment will usually include two preparatory sessions and at least three allergy-specific sessions within 15 weeks.
- •d) Patients 4 years and older
- •e) Signed written informed consent to participate in this clinical trial and willingness and ability to participate.
排除标准
- •a) Psychiatric illness and/or inability to give informed consent.
- •b) Off-label use (use not within the IFU).
- •c) Exclusion of patients due to contraindications in the IFU.
研究者
相似试验
已完成
4 期
This is multi-center, known drug with no comparator drug, clinical study to evaluate safety and efficacy of OmaliRel™ in patients with moderate to severe persistent asthma.CTRI/2021/05/033508Reliance Life Sciences Pvt Ltd220
招募中
不适用
Prospective, open-label, multicenter, single-arm, post-marketingstudy to assess the performance and safety of Vliwasorb® Prowound healingDRKS00031365ohmann & Rauscher GmbH & Co.KG135
进行中（未招募）
1 期
Single-arm pharmacokinetic phase 2a study of a single dose intravenous human plasma-derived C1-INH involving 20 HAE type I or type II patients, aged 18 years or olderEUCTR2019-001693-28-DEOctapharma Pharmazeutika Produktionsges.m.b.H.20
已完成
2 期
Pharmacokinetics and safety of IV Injection of OCTA-C1-INH in hereditary angioedemaISRCTN36746902Octapharma (Austria)20
尚未招募
不适用
Safety and performance of Intraocular LensCTRI/2022/01/039593Omni Lens Pvt Ltd